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Abstract 
Introduction 
Ultrasound guided fine needle aspiration cytology (UGFNAC) is commonly carried out in the 
head and neck.  The aim was to examine the amount pain experienced by patients undergoing 
this procedure carried out without the use of local anaesthetic. 
Methods 
A questionnaire was given to 109 consecutive patients undergoing UGFNAC containing a 
Visual analogue scale (VAS). Patients were asked to mark with a vertical line on the 100mm 
horizontal scale amount of pain they experienced during the biopsy. The pain was 
subsequently categorised as ‘no pain’, ‘mild pain’, ‘moderate pain’ or ‘severe pain’ based on 
previous pain studies.  
Results 
100 patients completed the VAS section of the questionnaire satisfactorily. 21 patients 
experienced no pain, 62 experienced mild pain and 17 experienced moderate pain. No 
patients experienced severe pain. Further analysis showed females had significantly higher 
VAS scores (Man-Whitney test: U = 925.5, z = 2.211, P = 0.027). Patients who were aware they 
were going to have a biopsy had significantly lower VAS scores than those who were not 
aware (Mann-Whitney test: U = 859.5, z = 2.263, P = 0.024). 
Conclusions 
UGFNAC is generally a well-tolerated procedure with pain scores being higher in females.  It 
is advised that patients are told by the referring clinician the need for biopsy as this reduces 
the amount of pain experienced. 
  
Introduction 
Ultrasound guided fine needle aspiration cytology (UGFNAC) is a commonly performed 
procedure in the radiological assessment of patients with a head and neck swelling.  Indeed, 
ultrasound guided assessment and biopsy of neck lumps is now recommended in the most 
recent NICE guidance on the management of upper aerodigestive tract cancer.1 It is not 
unreasonable to assume therefore that there will be a greater demand for ultrasound guided 
fine needle aspiration neck biopsy. UGFNAC is a quick and relatively easy technique to 
perform in an outpatient department. The technique has a high accuracy for both lymph node 
and salivary gland lesions.2,3,4  
Generally, local anaesthesia is not used when we carry out UGFNAC, as in our clinical 
experience most patients tolerate the procedure well. The procedure is fully explained to the 
patient beforehand and the patients’ anxieties allayed as much as possible. 
The data arose from an audit/service review comprising a patient satisfaction questionnaire 
given to patients attending the department. Part of the purpose of the audit was to evaluate 
the pain experienced by adult patients undergoing UGFNAC of lesions in the head and neck.   
  
Methods 
This work formed part of a registered audit/service review.  109 consecutive patients were 
given a questionnaire to complete after undergoing fine needle aspiration of extra-thyroid 
lesion/s in the head and neck.  The questionnaire covered the service provided by the 
department but also included a question on the amount of pain the patient experienced 
during the biopsy.  
Patients underwent high resolution ultrasound of the head and neck using a Toshiba Aplio 
500 ultrasound machine (Toshiba Medical Systems, Otawara-Shi, Japan). using either a 
18MHz or a 14MHz ultrasound probe.  If biopsy was required, the procedure was explained 
to the patient and verbal consent obtained. 
The biopsy was carried out using an aseptic technique without local anaesthetic.  The needle 
is inserted adjacent to the centre of the short axis of the probe. Once the lesion was 
penetrated, the needle was gently rotated and moved backwards and forwards to obtain the 
sample.  A capillary method was used with no suction applied to the needle aspiration 
In most cases the sample was obtained using a 21G (green) needle although occasionally 
other needle types were used; 23G (blue needle) or a 22G spinal needle for deeper lesions.  
The biopsies were performed by a Consultant Dental and Maxillofacial Radiologist and an 
experienced trainee in Dental and Maxillofacial Radiology. 
The age, gender, biopsy site, needle type, operator and number of passes made was recorded 
on the back of the questionnaire.  In some cases, the patient was aware that the biopsy was 
going to be performed prior to the appointment and this was also recorded. It was also 
recorded whether an information sheet on UGFNAC had been given to the patient prior to 
the appointment. 
The patient was then given the questionnaire to complete in the waiting room anonymously 
and without coercion from the radiologist performing the procedure.  Once completed it was 
handed back to the clinic coordinator.  The questionnaire included a visual analogue scale 
(VAS) (Fig 1). The patient was asked to mark with a vertical line on a 100mm horizontal scale 
the amount of pain they experienced during the biopsy. The ends of the scale were marked 
‘no pain’ and ‘pain cannot be worse’. There were no intermediary markings on the scale. 
Once returned, the VAS scores were measured to the nearest 1mm with a ruler. The score 
was then categorised into 4 groups: No pain (VAS score 0-4mm), mild pain (VAS score 5-
44mm), moderate pain (VAS score 45-74mm) and severe pain (VAS score 75-100mm), as 
suggested by Jensen, Chen and Brugger.5 
 
 
Statistical tests 
Descriptive statistics and graphical methods were used to explore the data initially. VAS scores 
were found to be heavily right-skewed and so medians as well as means are quoted here. 95% 
confidence intervals (95% CI) of the mean, standard deviations, and interquartile ranges are 
quoted also. The right-skew of the data could not be corrected via application of logarithms 
and so non-parametric tests were used here to test for differences between groups, namely, 
the Mann-Whitney test for all two-group comparisons and Kruskal-Wallis test (non-
parametric one-way ANOVA) for comparisons of three or more groups. Due to the heavy 
right-skew of the VAS data, the relationship between VAS score for males and females 
independently was explored using Spearman’s rank-correlation coefficient (rho) and also by 
gamma regression. Gamma regression is the preferred method when data is right-skewed 
and inspection of residuals showed that they followed a gamma distribution, as required. 
Median regression was also carried out (results not quoted here) and the results were found 
to be broadly similar to results of gamma regression. All inferential statistical tests were 
carried out using SPSS V23 and gamma regression was carried out using STATA V13. 
 
Results 
Of the 109 questionnaires given to the patients 100 had the VAS scale marked giving a 
response rate of 92%.  The subject and biopsy characteristics are given in Table 1. The mean 
age of the subjects was 58.17 years and the youngest subject was 18 years old and oldest 
subject was 96 years old. There were roughly equal numbers of males and females.  In the 
vast majority of cases (97%), the information sheet was not given to the patient. 38% of 
subjects were aware about the biopsy taking place and the procedure was carried out by two 
operators. In the vast majority of cases (97%), a green needle gauge was used and the median 
and modal average number of passes was equal to 2. The site for the procedure were mainly 
in the lymph node region (64%), salivary gland region (23%), both lymph node and salivary 
gland regions (4%), with “other areas”(i.e., cheek, lesion in supraclavicular fossa, lesion in 
occipital region) accounting for the remaining 9% of cases. 
 
The VAS scores grouped together into the pain categories is shown in table 2.  VAS scores as 
a function of various groupings are shown in Table 3. This shows that the females had 
significantly higher VAS scores (Mann-Whitney test: U = 925.5, z = 2.211, P = 0.027) than men, 
where the difference in mean VAS scores between males and females was 9.414 (95% CI: 
1.707 to 17.121). Furthermore, those subjects that were aware about the biopsy had 
significantly lower VAS scores than those subjects who were not aware (Mann-Whitney test: 
U = 859.5, z = 2.263, P = 0.024), where the difference in mean VAS scores between “aware” 
and “not aware” was 7.6 40 (95% CI: –0.373 to 15.654). Although there was some evidence 
that VAS scores increased with increasing number of passes up to the 3 passes, no significant 
differences occurred (Kruskal-Wallis test: Chi-square = 3.812, DOF = 3, P = 0.283). 
Furthermore, 4 or more passes demonstrated anomalous results (e.g., mean VAS score = 16). 
Finally, there was no significant differences in VAS scores by site (either lymph node or salivary 
gland: Mann-Whitney test: U = 612, z = 1.194, P = 0.232) or by operator : Mann-Whitney test: 
U = 842, z = 0.57, P = 0.569). Sample sizes were too low in some groups for the other variables 
(e.g., needle gauge) to allow reliable quantitative comparison of VAS scores for these 
variables.  
 
The relationship between VAS and age (in years) was investigated using scatter plots, as 
shown in Fig. 1. “Lines of best fit” shown in these figures were formed using gamma 
regression, which is appropriate for right-skewed data. We see that VAS scores for males 
reduce strongly with age. It was found that the line of best fit of VAS scores scaled with age 
(in years) followed the expression: VAS = 60.9244 × exp{–0.0229 × age}. This result indicates 
a statistically significant 2.26% “compound” reduction (z = –2.92 and P = 0.003) in VAS each 
year for males only, e.g., an initial value of VAS = 30.0 reduces to VAS = 30.0 × exp{–0.0229 × 
50} = 9.5 over 50 years. We see from Fig. 1 that VAS scores for females reduce slightly with 
age. It was found that the line of best fit of VAS scores scaled with age (in years) followed the 
expression: 32.7828 × exp{–0.0030 × age}. This result indicates a 0.3% “compound” reduction 
(z = –0.60 and P = 0.545) in VAS each year for females only, e.g., an initial value of VAS = 30.0 
reduces to VAS = 30.0 × exp{–0.0030 × 50} = 25.8 over 50 years. Finally, results for Spearman’s 
correlation coefficient (rho) of VAS with age agree with all of these results presented above, 
i.e., rho for males = –0.364 (P = 0.012) and rho for females = –0.021 (P = 0.825). Thus, males 
again demonstrate a negative correlation of VAS scores with age that is significant, whereas 
females demonstrate (at best) a very weak negative correlation of VAS scores with age. 
 
Discussion 
VAS is a well-established technique for the assessment of pain following UGFNAC.6-9 Our 
results demonstrated that most patients experienced either mild pain (n=62) or no pain 
(n=21).  17 patients experienced moderate pain, and none experienced severe pain.  The cut 
off points of the categories were those suggested by Jensen.5 The pain categories are based 
on the distribution of pain following surgery,10 but they have subsequently been used to 
evaluate pain following biopsy in the head and neck.9 
VAS has been shown to be a reliable and valid method of assessing acute pain.11 VAS is quick 
and simple to carry out and has been used in several studies assessing pain following fine 
needle aspiration biopsy of lesions in the head and neck.6,8,12 Other established methods of 
pain assessment include the Numeric Rating Scale (NRS) and the Verbal Rating Scale (VRS), 
both of which can also be carried out graphically.  The NRS is quick and easy to score but has 
been shown to have poor reproducibility.13 VAS is more sensitive than VRS because a larger 
change is required before it becomes evident on the scale.14 Overall VAS seems to be the most 
statistically robust method of assessing pain .14 
We found that women had a significantly higher VAS score than males, a finding also reported 
following biopsy of thyroid nodules.9 There is strong evidence of an increased sensitivity to 
pain and pain threshold in women.15,16 Although the reasons for the differences in pain 
perception between the sexes is unknown it is thought to be multifactorial with genotype and 
endogenous opioid functioning playing a major role.17  Sex hormones are also thought to play 
an important role in pain perception.17  However it should be noted that other studies have 
found no differences in pain perception between the genders during biopsy. 7,18 
Age differences in pain perception are not well understood,19 with some studies reporting an 
increase in experimental pain in older adults and others reporting the opposite findings. 20,21 
However, several studies have reported no differences in pain scores and age.6,9,18,22 We 
found that VAS scores for males reduced markedly with age and the VAS scores for females 
reducing slightly with age.  Overall our findings support the findings of a recent study that 
reported higher VAS scores in younger patients.23 
 
Anxiety may also play a role in pain perception.24 This may partially explain why those patients 
who knew they were going to have a biopsy generally reported lower pain scores. Presumably 
these patients had time to assimilate the information and were therefore less anxious about 
the procedure.  As far as we are aware, this finding has not been reported before in relation 
to UGFNAC in the head and neck.  The sample size was too small to examine whether the 
information sheet would be helpful, but it seems sensible to provide one whenever possible 
to allay patients’ concerns. One of the action points following the audit was to produce a 
patient information video on what to expect when having a biopsy carried out. 
In our audit/service review we found no differences in VAS scores between the two operators. 
Although one of the operators was a trainee they were experienced in performing the 
procedure.  A previous study also showed no differences in pain scores between radiologists 
with different levels of experience.22 
A study on thyroid FNAC found that pain scores were related to the number of passes.23 Our 
results showed there was some evidence of increase in pain scores with the number of passes, 
but this was not significant. Furthermore, the pain scores for 3 passes were generally higher 
than for 4 passes indicating larger sample sizes are required to look at this effect. 
When we compared the pain scores from biopsies of the salivary glands with those from 
lymph nodes we found no significant differences. In a recent study by Lo et al. they found that 
pain scores from lymph nodes were significantly higher than thyroid nodules. The authors 
were not clear why there was a difference but proposed this may partly be due to the 
distribution of sensory nerve endings in the neck.25 
We did not record the depth of the lesion in our audit data set, but it is known that there is 
an association between lesion depth in the thyroid and increased VAS score.18  Thyroid biopsy 
was not included in this audit/service review as these procedures are performed by a different 
team. 
We do not routinely use any topical or injected local anaesthetic during UGFNAC. There are 
conflicting results on whether topical local anaesthetic is useful.6,9 In addition, the use of 
topical anaesthetic potentially increases the appointment time and adds to the overall cost 
of the procedure.  Alternatively, local anaesthetic can be injected prior to UGFNAC. Despite 
some papers advocating local anaesthetic injection before ultrasound guided biopsy in other 
sites such as prostate,26 pain scores can be higher using this technique in the head and neck.12  
For this reason, it is not recommended to use this technique if there is going to be only a 
single pass of the biopsy needle. 
In the United Kingdom, recently published National Institute for Clinical Excellence guidance 
in the management of patients with upper aerodigestive tract cancer recommends the use of 
ultrasound guided biopsy as part of the assessment of a neck swelling.1 While the 
presentation of a ‘neck lump’ encompasses a range of benign and malignant diseases, 
differentiating between the two may only be possible with UGFNAC.  Certainly, the role of 
ultrasound in the diagnostic work up of these patients will increase. While different models 
of access to this type of service exist throughout the UK, our work highlights some useful 
findings which may be taken into consideration when designing a patient centred neck lump 
service. 
 
Conclusions 
 FNAC is generally well tolerated procedure with most patients experiencing either 
mild pain or no pain during the procedure. No patients experienced severe pain. 
 There was no difference in VAS scores between lymph node biopsy and salivary gland 
biopsy. 
 VAS scores were significantly higher in females than males. 
 VAS scores for males reduced markedly with age.  
 VAS scores were higher in those patients who were not aware they were going to have 
a biopsy before the appointment. It is advised therefore that patients are told by the 
referring clinician the need for biopsy and if possible provide the patient with 
information on the procedure prior to the appointment. 
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Tables and figures 
Table 1. Subject and biopsy characteristics. 
 
 Mean Median Minimum Maximum 
Age (years) 58.17 60 18 96 
Gender Males (n = 47) Females (n = 53)   
Information sheet 
given to patient 
Yes (n = 3) No (n = 97)   
Aware about biopsy 
taking place 
Yes (n = 38) No (n = 62)   
Operator 
consultant  
(n = 65) 
trainee 
(n = 28) 
Both (n = 7)  
Needle gauge used 
for biopsy 
21G, Green (n = 
97) 
23G, Blue (n = 1) 
Both 21G 
and 23G (n = 
1) 
Spinal needle 
(22G) (n=1) 
Number of passes 
made with the needle 
into lesion 
1 Pass (n = 28) 2 Passes (n = 50) 
2 Passes (n = 
13) 
4 or more 
passes (n = 9) 
Site 
Lymph Nodes 
(LN)  
(n = 64) 
Salivary Gland 
(SG) 
(n = 23) 
Both LN & 
SG 
(n = 4) 
Other 
(n = 9) 
 
  
Table 2 VAS scores grouped into pain categories 
 
 
 
 
 
 
  
VAS score Pain Category Frequency 
0-4mm No pain 21 
5-44mm Mild pain 62 
45-74mm Moderate pain 17 
75-100mm Severe pain 0 
Total  100 
Table 3: VAS scores for various groupings.  
 Mean (95% CI) 
Sample standard 
deviation 
Median IQR 
Males  
17.51 (12.48 to 
22.54) 
17.141 12 
25 
Females  
26.92 (21.09 to 
32.76) 
21.169 22 
32 
Aware = Yes  
17.76 (11.22 to 
24.31) 
19.917 10.5 
28 
Aware = No  
25.40 (20.47 to 
30.33) 
19.406 22 
30 
1 Pass  
18.29 (11.84 to 
24.74) 
16.635 13 
28 
2 Passes  
23.53 (17.74 to 
29.30) 
20.322 19.5 
35 
3 Passes  
32.15 (19.53 to 
44.78) 
20.888 31 
37 
4 or More 
Passes  
16.00 (< 0 to 33.06) 22.192 5 
14 
Lymph Nodes 
24.67 (19.61 to 
29.74) 
20.276 19 
33 
Salivary Glands 
19.30 (11.18 to 
27.43) 
18.792 13 
24 
Operator 
(consultant) 
22.05 (17.26 to 
26.84) 
19.335 18 
32 
Operator 
(Trainee) 
20.11 (12.85 to 
27.37) 
18.719 16 
26 
All subjects 
22.50 (18.56 to 
26.44) 
19.854 18 
34 
 
  
Figure 1: The VAS question that the patients were asked to answer. 
 
 
  
Figure 2: Results of gamma regression of VAS as a function of age for males and females 
separately.  
 
 
